PIK3CA and cholangiocarcinoma: A phase 2 study (NCT02631590) investigating the PI3K inhibitor copanlisib in combination with gemcitabine and cisplatin for an unselective patient population with advanced CCA revealed no significant difference in mOS when copanlisib was added to standard chemotherapy [216].